Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease.
Tuñón J, Fernández-Fernández B, Carda R, Pello AM, Cristóbal C, Tarín N, Aceña Á, González-Casaus ML, Huelmos A, Alonso J, Lorenzo Ó, González-Parra E, Hernández-González I, Mahíllo-Fernández I, López-Bescós L, Egido J.
Tuñón J, et al.
Diabetes Metab Res Rev. 2016 Oct;32(7):685-693. doi: 10.1002/dmrr.2787. Epub 2016 Apr 25.
Diabetes Metab Res Rev. 2016.
PMID: 26888181